Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions Inc (BLFS)
:BLFS
Holding BLFS?
Track your performance easily
BLFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.50 - $28.88
Previous CloseN/A
Volume44.73K
Average Volume (3M)275.17K
Market Cap
$1.23B
Enterprise Value$1.16B
Total Cash (Recent Filing)$1.41M
Total Debt (Recent Filing)$2.84M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Mar 13, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding46,387,215
10 Day Avg. Volume232,825
30 Day Avg. Volume275,169
Standard Deviation0.20
R-Squared0.27
Alpha0.00501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.83
Price to Cash Flow (P/CF)63.10
P/FCF Ratio63.10
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue9.41
Enterprise Value/Gross Profit24.84
Enterprise Value/Ebitda-74.28
Forecast
1Y Price Target
$30.78Price Target Upside17.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BioLife Solutions News
PremiumCompany Announcements
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Bulls Say, Bears Say
Bulls Say
Market PositionBioLife maintains a significant presence in the cell and gene therapy sector, holding over 70% market share in relevant commercially-approved therapies, positioning it well for future growth.
Revenue GrowthBioLife Solutions has reported preliminary fourth-quarter revenue that exceeded expectations, highlighting strong performance in cell processing with a 37% increase year-over-year.
Strategic RealignmentThe company has successfully completed the divestiture of its freezer business, aligning with its strategic focus on high-margin, recurring-revenue cell processing products, which is expected to enhance profitability.
Bears Say
Business PerformanceBiolife's freezer business lines represented a high-spend and low-margin segment, which weighed on top-line growth and the share price.
Projected RevenuesProjected revenues for the next 12 months are lowered, resulting in a reduced price target of $27 per share.
Revenue GuidanceBioLife lowered revenue guidance to $98M-$100M, from $99M-$101M, to factor in the reduction of the SciSafe divestiture.
---
Ownership Overview
21.99% Insiders
24.39% Mutual Funds
0.51% Other Institutional Investors
35.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLFS FAQ
What was BioLife Solutions Inc’s price range in the past 12 months?
BioLife Solutions Inc lowest stock price was $14.50 and its highest was $28.88 in the past 12 months.
What is BioLife Solutions Inc’s market cap?
BioLife Solutions Inc’s market cap is $1.23B.
When is BioLife Solutions Inc’s upcoming earnings report date?
BioLife Solutions Inc’s upcoming earnings report date is Mar 13, 2025 which is in 51 days.
How were BioLife Solutions Inc’s earnings last quarter?
BioLife Solutions Inc released its earnings results on Nov 12, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.038.
Is BioLife Solutions Inc overvalued?
According to Wall Street analysts BioLife Solutions Inc’s price is currently Undervalued.
Does BioLife Solutions Inc pay dividends?
BioLife Solutions Inc does not currently pay dividends.
What is BioLife Solutions Inc’s EPS estimate?
BioLife Solutions Inc’s EPS estimate is -0.06.
How many shares outstanding does BioLife Solutions Inc have?
BioLife Solutions Inc has 46,387,215 shares outstanding.
What happened to BioLife Solutions Inc’s price movement after its last earnings report?
BioLife Solutions Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -9.019%.
Which hedge fund is a major shareholder of BioLife Solutions Inc?
Among the largest hedge funds holding BioLife Solutions Inc’s share is Royce & Associates LLC. It holds BioLife Solutions Inc’s shares valued at 21M.
---
BioLife Solutions Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.78 (17.75% Upside)
$30.78 (17.75% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 75.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.24%
12-Months-Change
Fundamentals
Return on Equity
-9.87%
Trailing 12-Months
Asset Growth
-7.17%
Trailing 12-Months
Company Description
BioLife Solutions Inc
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
---
BLFS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and margin expansion driven by the cell processing platform. The strategic divestiture of the SciSafe BioStorage business is expected to streamline operations and improve the company's financial position. However, the reduction in overall revenue guidance and the dependency on a small customer base are notable concerns.Read More>---
BLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
---
BLFS Stock 12 Month Forecast
Average Price Target
$30.78
▲(17.75% Upside)
Technical Analysis
Fate Therapeutics
―
AxoGen
―
Staar Surgical
―
Alphatec Holdings
―
TransMedics Group
―
Accelerate Diagnostics
―
Best Analysts Covering BLFS
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+48.11%
assigned a buy rating 8 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.11% per trade.
---